Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

450.000
+0.2000.04%
Volume:339.53K
Turnover:151.29M
Market Cap:107.55B
PE:-271.60
High:451.400
Open:438.000
Low:436.600
Close:449.800
52wk High:562.500
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.85
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.657
ROE:2.92%
ROA:-0.04%
PB:17.19
PE(LYR):-271.60
PS:43.97

Loading ...

Kelun-Biotech to Debut Phase 3 TroFuse-005 Sac-TMT Endometrial Cancer Data at ESMO 2026 Presidential Symposium

Reuters
·
Yesterday

China Universal Asset Management Raises Stake in SKB BIO (06990) by 62,000 Shares at Approximately HK$454.07 Each

Stock News
·
Yesterday

SKB BIO: Gexin Liu Disposes of Shares, Long Position Falls to 49.28%

HK Disclosure
·
Oct 09

SKB BIO: Gexin Liu Disposes of Shares, Long Position Falls to 49.32%

HK Disclosure
·
Oct 09

JPMorgan Unfazed by Rising Rates Impact on China Healthcare, Remains Bullish on Biotech and CXO

Stock News
·
Oct 06

Movement Alert|SKB BIO Falls 3.45% in Regular Trading, Biotech Sector Under Broad Selling Pressure

Market Focus
·
Oct 02

Movement Alert|SKB BIO Rises 3.42% in Regular Trading, TROP2 ADC Sac-TMT Studies Selected as LBA at ESMO Conference Amid Sector Rally

Market Focus
·
Sep 30

SKB BIO: DFZQ Acquires Shares, Long Position Rises to 5.0%

HK Disclosure
·
Sep 29

Movement Alert|SKB BIO Rises 4.17% in Regular Trading, Multiple Studies Selected as Late-Breaking Abstracts at ESMO Plus Biotech Sector Resonance

Market Focus
·
Sep 29

SKB BIO (06990): 汇添富基金管理股份有限公司 Acquires Shares, Long Position Rises to 5.0%

HK Disclosure
·
Sep 24

Kelun-Biotech Says Phase 3 OptiTROP-Lung06 Sacituzumab Tirumotecan Plus Pembrolizumab Trial Wins ESMO 2026 Late-Breaker Slot

Reuters
·
Sep 22

Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Stock News
·
Sep 21

HK Movers | Innovative Drug Stocks Rally Broadly; LEPU BIO, INNOCARE, AKESO Jump Over 7%

Tiger Newspress
·
Sep 21

Movement Alert|SKB BIO Rises 3.34% in Regular Trading, Buoyed by First-Half Profitability Milestone and Pipeline Progress

Market Focus
·
Sep 21

DFZQ disposes 15,100 shares of SKB BIO

HK Disclosure
·
Sep 17

SKB BIO: 汇添富基金管理股份有限公司 Disposes of Shares, Long Position Falls to 4.99%

HK Disclosure
·
Sep 16

Hong Kong Stock Market Update: SKB Bio Surges Over 3% Following Positive Phase 2 Trial Results and Initiation of Phase 3 Study

Stock News
·
Sep 14

Kelun-Biotech Says Phase III Trial Shows Trastuzumab Botidotin Extends PFS vs T-DM1 in HER2+ Metastatic Breast Cancer

Reuters
·
Sep 14

SKB Biopharma's Partner Sees Positive Results from Asthma Drug Trial

MT Newswires Live
·
Sep 08

SKB BIO Announces Positive Phase 2 Interim Data and Phase 3 Launch for Asthma Antibody SKB378/WIN378

Bulletin Express
·
Sep 08